Search This Blog

Thursday, May 31, 2018

CMS’ Verma: Data blocking will not be tolerated


Since data could be exchanged, providers have been accused of hoarding it.
Government pressure and business incentives may be changing that.
CMS Administrator Seema Verma told a packed room of health care execs earlier this year that it would no longer be tolerated.
“Let me be crystal clear, the days of finding creative ways to trap patients in your system must end. It’s not acceptable to limit patient records or to prevent them and their doctor from seeing their complete history outside of a particular healthcare system,” she said speaking at HIMSS in March.
In addition, within months the Office of the National Coordinator, as mandated under the 21st Century Cures Act, will issue a proposed rule to set ground rules to prevent data blocking. Efforts tackling the issue couldn’t have come at a better time.
At the same time, digital health startups are beginning to accrue value and build out robust data sets. From platform companies such as Vida Health to digital therapeutics like Omada Health, big data is becoming more important than ever. Roche, for example, was willing to shell out $1.9 billion to acquire oncology EHR company Flatiron Health, largely for its data set.
As these tools and datasets proliferate, providing interoperability will be an important milestone for transitioning to the next stage of American healthcare delivery, Allscripts CEO Paul Black said at HLTH 2018 earlier this month.
Data sharing among disparate parties will be critical to realize the benefits of integrating new tools into the clinical setting. Companies may be more inclined to share under the pressure of government and business incentives.

The cause for concern

The universe of digital health companies is expanding. Digital health funding for the first quarter of this year hit a new high of $162 billion across 77 deals, up from $141 billion in the same period last year, according to Rock Health. Among the top value propositions was disease monitoring as well as consumer health information and R&D catalysts.
What many of these startups have in common is the need for aggregated data that cross the silos of multiple health record systems. Getting at that data can be difficult, if not impossible at times, but interconnectedness is imperative if the next generation of digital health solutions are to realize their potential. “It’s been improving a little bit over time, but traditionally it’s been the case it’s very hard to get the data out of the health record system,” Bill Evans, managing director of Rock Health said in an interview.
Stephanie Tilenius, CEO of Vida Health, acknowledges the risk of data hoarding.
“Over the past few years, IoT and smart sensors have led to an explosion of connected devices and, in turn, an explosion of different and closed (or blocked) data formats,” she wrote to Healthcare Dive in an email. Digital health firms that aggregate data are all working to increase data sharing, but each is responding in its own way, “which is endemic to the problem itself,” she wrote.
Vida provides personalized health coaching and programs for patients who can then share data and insight summaries with providers.
Interoperability and data sharing with competitors is often “an afterthought,” says Dan Wilson, founder and CEO of Moxe Health, which facilitates bidirectional movement of clinical data.
“All of a sudden you’re big, you have a lot of data, people are asking for access to it and businesses, consistently, feel they’ve earned the right to that proprietary advantage,” he said.
Evans said he sees Verma’s admonition as a call to EHRs to break down their silos so innovators can aggregate data in new ways to improve health and healthcare processes. The challenge is getting established companies to tear down their walls.

Data sharing importance increasing to manage conditions

With the move to value-based payment models, providing clinical or predictive patient insights to providers and insurers can increase the importance of a dataset.
At Omada Health, an individual’s percentage of weight loss is reported to substantiate outcomes-based billing, and health information is provided back to participants. Users also have access to information through a real-time, online dashboard, Lucia Savage, chief privacy and regulatory officer at diabetes coaching firm Omada told Healthcare Dive in an interview.
Meanwhile, Moxe also works with providers and insurers to facilitate the exchange of clinical data to support billing claims. But it doesn’t stop there, Wilson said. As insurers accrue data, they have a much broader view of what it might mean for gaps in care.
At UPMC, reducing information blocking meant creating a data extraction layer in its network that “allows for us really to have data as an asset across our organization and allows for us to create a rich ecosystem of innovations on top of the data that are adherent to national standards and FHIR-ready,” Rasu Shrestha, chief innovation officer at the University of Pittsburgh Medical Center, told Healthcare Dive in an interview.
UPMC is pushing this framework with some of its portfolio companies at its innovation arm UPMC Enterprises, such as Health Catalyst. Through a process called late-binding architecture, researchers and providers can extract information and enable clinical and operational applications to occur atop the Health Catalyst platform, Shrestha said.
“At the end of the day, that really is what the conversation should be about,” he said. “It’s less about the data and more about the knowledge and the information you garner … and making those attributes then actionable at the point of decision-making.”

Breaking down traditional barriers

For EHRs, companies like athenahealth and Allscripts realized fairly early on that they needed to focus on an open platform, notes Wilson. But others have been slower to do so. In some cases, vendors have turned it into a business model with fees to gain access to data — usually in the 15% to 30% of revenues level, he said.
“I would like to see more focus on APIs that make data available,” Wilson said.
He would also like to see a more supportive environment for those who speak out about data blocking. “Everyone’s afraid of doing it,” Wilson says. “Almost by definition, the people who are most impacted are the ones with the least amount of power in the market. And so if you come forward as your standard whistleblower and you don’t have the right protections, it’s going to be very costly.”
Those costs can be the death knell for an early startup. It can take months to work through an allegation of data blocking, during which investors and customers are likely to shy away. “As a result, people are suffering in silence trying to figure out how to persevere and make something happen,” Wilson said.
The 21st Century Cures Act, signed into law by former President Barack Obama, encourages interoperability of EHRs and patient access to personal health data and discourages information blocking. President Donald Trump’s administration last October issued guidance for providerson when and how to attest they are not engaged in data blocking and are willingly sharing information with patients. Under the Cures Act, providers and EHR vendors that engage in data blocking could face fines of up to $1 million per violation. The guidance is aimed at providers participating in the Quality Payment Program’s Merit-based Incentive Payment System.
In addition, CMS in its hospital inpatient payment program proposed rule in May called for feedback on whether issuing a new condition of participation for hospitals to “require electronic exchange of medically necessary information” would help to reduce information blocking.
Some involved in the digital health world would like to see more clarity from the government on what is and is not allowable in terms of data exchange. “If I had a magic wand, it would be that HHS doubles down on helping provide industry guidance around how to deal with the emerging complexity,” Evans says.

Here’s why digital health companies are likely to share

As the digital health field matures, companies are moving beyond fitness trackers and basic monitors to tools that seek to offer deeper insights into an individual’s personal health status and help inform care decisions. The challenge isn’t so much about who has access to the data, but what new and interesting ways developers can use the same data. The common need for data access is fueling a move away from proprietary file formats and any perception of data blocking, some observers say.
“Startups that are worth their weight in salt have totally adopted a much more open architecture and … business model [that] is not tempered on blocking of information,” Shrestha said. “Their business model is creating value out of insights that can be generated from the data.”

Readmits may be higher for bundled care payments: Avalere

  • Readmission rates for conditions that are a part of the Bundled Payment for Care Improvement Advanced (BPCI-A) payment model can vary by up to six times, according to a new report from Avalere.
  • The study found that 90-day readmission rates in 2017 were highest for certain liver disorders (43%) and lowest for major joint replacements of upper extremity (7%). The average across the conditions studied was 26%. Rate of readmission is one of seven quality measures the CMS bundled model uses to determine eligibility for bonus payments.
  • The first group of BPCI-A participants will begin the model on Oct. 1, and the deadline for the second cohort of applications is Aug. 1.

Bundled payment models are a focal area for the movement toward value-based reimbursement. Although data show mixed success in reducing costs and improving health outcomes, multiple payers and providers are pursuing these models in the hopes of finding a successful and scalable method.
Avalere said that organizations participating in BPCI-A could use the readmission rate information to focus improvement efforts on certain conditions, and not necessarily surgical episodes typically targeted in readmissions. “In our experience, organizations that more carefully evaluate and select episodes for participation tend to be more successful in episodic bundled payment programs,” Erica Breese, director at Avalere, said in a statement.
CMS launched the much-anticipated BPCI-A in January as a voluntary model that includes 32 clinical episodes, three of which are outpatient. It builds off the original BCPI, which the Center for Medicare and Medicaid Innovation (CMMI) began in 2013 and has grown to include more than 400 organizations.
The original BPCI produced scattered results, and evaluation has been difficult because of numerous variables and options available under the model. One outcome CMS will hope not to reproduce was a relative lack of interest. Only 12% of eligible hospitals signed up for BCPI and nearly half of them dropped out for at least one condition, according to a report from JAMA.
One overall sticking point for bundled programs is whether they need to be mandatory to show improvement. It was no surprise that CMS chose to leave BCPI-A as voluntary, considering current management’s focus on avoiding excessive reporting burdens, but some policy experts still believe forced participation is necessary.
As more groups join BPCI-A, there is also concern it will overlap with other advanced payment models, particularly the Medicare Shared Savings Program (MSSP). If CMS does not address the issue, there could be “far-reaching impact on provider incentives and behavior,” according to a Health Affairs blog post last month.
That same worry was echoed recently in comments on CMMI’s proposal for direct provider contracting. The American Medical Group Association suggested CMS focus on fixing MSSP’s flaws instead of pursuing other, potentially redundant models.
Healthcare organizations are realizing the question they face is not whether to participate in value-based payment, but what method will work best for them.
As Darcie Hurteau, senior director of informatics at the policy and analytics firm DataGen told Healthcare Dive earlier this year, “This is the direction the industry is headed in, and practices will need to pay attention if they want to stay competitive.”

Dova bought newly approved drug castoff for a song but payers will rue price

Dova $DOVA didn’t have to pay much when it bagged the rights to Doptelet (avatrombopag) from Eisai — laying out only $5 million for the castoff. And now that the FDA has come through with a marketing approval for a set of chronic liver disease patients suffering from low blood platelet counts, it’s not passing on any of the savings.
Dova reported today that it’s slapped a wholesale list price of $9,000 for the 40 mg daily dose and $13,500 for the 60 mg daily dose, which raised the eyebrows of Leerink’s Geoffrey Porges — who’s been tracking the launch.

In many cases, says Porges, the cost of the pre-treatment regimen the drug is good for will outstrip the cost of the procedure patients require. He noted:
This is above our and consensus expectations and will test the market’s appetite for premium pricing for specialty therapeutics. Over the next few months, this price will also stretch Dova’s capacity for co-pay assistance and temporary free goods as payers prepare and implement their coverage policies for this medicine. Even in this indication, it is hard to predict how payers will react to a pre-treatment regimen whose cost is significantly higher, in many cases, than the procedure itself (e.g., dental extraction, uncomplicated endoscopy, etc.).
There are about 70,0000 chronic liver disease patients who suffer from thrombocytopenia. Standard operating procedure here is to assure patients that the company will work to limit any out-of-pocket expenses, and Dova is walking the line.
“We remain committed to ensuring access to Doptelet through Dova 1Source, our physician and patient reimbursement support center,” said CEO Alex Sapir.

Ironwood dodges activist board seat, but the investor still has words of advice

Ironwood has successfully fended off activist investor Alex Denner from joining its board, the company announced Thursday following a shareholder meeting. But Denner isn’t done giving out tips.
Denner’s company Sarissa Capital took a stake in Ironwood late last year, and soon after announced plans to snag a seat at the table. Ironwood $IRWD campaigned for shareholders to reject Denner earlier this month, although it first seemed open to the idea. Denner is probably best known as Carl Icahn’s protégé, with a history of spurring acquisitions of the companies in which he invests. He served as chairman of Ariad before Takeda acquired the cancer company for $5.2 billion last year. He was also a board member at Bioverativ before it was sold to Sanofi for $11.6 billion earlier this year. And he recently took control of The Medicines Co $MDCO amid considerable buzz.
But after three meetings with Denner to better understand his intentions for the company, Ironwood’s executives decided they weren’t thrilled with the prospect of him on their board. In a statement, the company said Sarissa hadn’t made a strong enough case to appoint Denner, considering the boards existing diversity.
Shareholders apparently agree, as they voted Thursday to appoint three independent directors who were up for re-election rather than bring in Denner.
“We look forward to continuing to engage with our shareholders as we seek to deliver on our 2018 goals and to execute on our intent to separate Ironwood into two focused and durable businesses each with substantial opportunity for long-term growth and value creation,” Ironwood said.
Under pressure from Denner to boost shareholder value, Ironwood said earlier this month it would soon split into two companies: spinning out a pipeline of early- and mid-stage drugs into a separate, publicly traded biotech company while keeping its marketed products and related development projects in house at a scaled down, and more profitable, mother company.
Denner thinks that’s a good idea and had more advice to offer. Just after Ironwood announced its board vote results, Denner released a statement of his own. He wants three things from Ironwood:
The two post-spinout companies should be completely separate entities without cross-ownership.
Each company should have modern, shareholder-friendly governance without classified boards, supervoting stock, etc.
Capital allocation should be optimal. For example, adding significant debt to one company to capitalize the other or an IPO of 20% of one of the companies in order to capitalize the other would destroy significant shareholder value.

Wildfire smoke off the radar for research until recently


Emily Fischer is likely one of the few people whose summer plans were buoyed by a recent forecast that much of the western United States faces another worse-than-normal wildfire season. Unusually warm weather and drought, together with plenty of dry grass and brush, are expected to create prime conditions for blazes this summer, federal officials announced on 10 May.
The forecast has local officials bracing for the worst. But it represents an opportunity for Fischer, an atmospheric scientist at Colorado State University in Fort Collins who is preparing to spend the summer flying through plumes of wildfire smoke aboard a C-130 cargo plane jammed full of scientific equipment. The flights are the highlight of an unprecedented effort, costing more than $30 million, that involves aircraft, satellites, instrumented vans, and even researchers traveling on foot. Over the next 2 years, two coordinated campaigns—one funded by the National Science Foundation (NSF), and the other by NASA and the National Oceanic and Atmospheric Administration (NOAA)—aim to better understand the chemistry and physics of wildfire smoke, as well as how it affects climate, air pollution, and human health.
“This is definitely the largest fire experiment that has ever happened,” says atmospheric chemist Carsten Warneke of NOAA’s Earth System Research Laboratory in Boulder, Colorado, one of the lead scientists. Wildfire smoke, he adds, is “one of the largest problems facing air quality and climate issues going forward.”
The problem is growing as the size and intensity of wildfires rise in the western United States, marinating communities in smoke. Wildfires account for more than two-thirds of the particulate matter in the West on days that exceed federal clean air standards, according to a 2016 study in the journal Climatic Change. And global warming is likely to stoke even more fire in coming years, by making wildlands more combustible. By midcentury, more than 80 million people living across much of the West can expect a 57% increase in the number of “smoke waves”—events that shroud a community for 2 days or more—according to the 2016 study. The consequences for public health could be sobering; smoke includes an array of noxious compounds and tiny particles that can complicate breathing and promote disease. Other parts of the Americas as well as Europe, Africa, Asia, and Australia are likely to experience the same climate-driven surge in wildfires, according to U.S. Forest Service researchers.
Despite the potential threat, wildfire smoke has received little sustained scientific attention. The two new campaigns aim to change that. This year, the NSF-funded team that includes Fischer aims to fly its instrumented C-130 through 15 to 20 wildfire plumes. And next year, researchers with NASA and NOAA will have access to a bigger aircraft—a DC-8 jet—that will scour smoky skies across the United States.
One goal is to inventory the chemicals released by wildfires, including nitrogen oxides and carbon monoxide, and a vast array of volatile organic compounds. Current models for predicting the chemical makeup of smoke, which rely largely on satellite observations, have a huge margin for error, Warneke says. In part, that’s because of uncertainty about how much vegetation wildfires consume. New studies that combine data from satellites, aircraft, and ground-based researchers scrutinizing burn sites should help fine-tune those estimates.
If wildfires are burning in the Pacific Northwest, what does that mean for Colorado … ?
Emily Fischer, Colorado State University
Researchers will also use the C-130 to chase plumes during their first 24 hours aloft, to see how the chemistry of smoke changes as it wafts through the atmosphere. In particular, they hope to get a more precise picture of what happens to the nitrogen released by burned vegetation, including how much is converted into nitrogen oxides that can contribute to ground-level ozone, a regulated pollutant that can worsen breathing problems. Such data, Fischer says, could help answer questions like: “If wildfires are burning in the Pacific Northwest, what does that mean for Colorado air quality?”
Researchers also plan to track the evolution of aerosols—minute particles that can either scatter or absorb sunlight, and play a major role in shaping climate. And they want to observe plumes as they collide with clouds, to better understand how the two affect each other. Smoke particles can alter cloud formation by acting as nuclei for ice particles, potentially influencing the weather, and cloud moisture can alter smoke chemistry. The results could help improve weather forecasts.
At night, falling temperatures can cause smoke plumes to sink into valleys, worsening air quality there. NOAA and NASA researchers will track the plumes with aircraft, vans, and a drone. That initiative will also involve DC-8 flights beyond the West, into the Midwest and Southeast, tracking smoke from fires intentionally set to clear farm fields and prescribed burns in forests. The goal of collecting such a wide array of data, Warneke says, is “to do the whole picture at one time and understand how the whole thing plays together.”
Beyond these projects, public health researchers are taking a growing interest in what happens when smoke blankets communities, sometimes for weeks at a time. Past studies have found that short-term smoke exposure can increase problems for people with asthma and other lung ailments, but “there’s really not much information at all” about the effects of long-term, chronic exposure, says Curtis Noonan, an environmental epidemiologist at the University of Montana in Missoula.
Noonan was at the center of some of the worst smoke of the 2017 wildfire season, when Montana was hit by fires that burned 400,000 hectares. The biggest blow fell on Seeley Lake, a town of 1600 located 50 kilometers northeast of Missoula. The nearby Rice Ridge fire filled the town with smoke for much of August and early September 2017, driving levels of fine particulate matter to nearly 20 times the acceptable limit set by the Environmental Protection Agency.
Noonan is now working with colleagues to gather health information from residents of Seeley Lake and several other Montana towns. They aim to track how respiratory performance, mental states, and genetic markers related to inflammation change when smoke descends. Noonan is also seeking funding to sift through health records of wildland firefighters to understand how sustained smoke exposure has affected them.
Farther north, Sarah Henderson, an environmental epidemiologist and veteran smoke researcher at the British Columbia Centre for Disease Control in Vancouver, Canada, hopes to track the fate of children born during high-smoke events. One big question, she says, is: “If you’re born into really smoky conditions with your extremely sensitive, newborn lungs, what does that mean for you?”
As scientists prepare to tackle such questions, health officials in Missoula are preparing for a possible repeat of last year’s smoke waves. The health department is stockpiling indoor air filters for day care centers, schools, and other gathering spots.
Fischer, for one, hopes they aren’t needed. Although she requires fire for her studies, she says, “I’m just wishing for an average wildfire year with wildfires in wilderness areas that don’t cause any property damage.”

FDA launches medical device ‘innovation challenge’ to combat opioid crisis


  • The Food and Drug Administration announced Wednesday an “innovation challenge” aimed at encouraging the development of medical devices such as digital health applications and diagnostic tests aimed at detecting, treating and preventing opioid addiction.
  • The agency is accepting proposals between June and September from developers with products at any stage of development, or with an existing product attempting to show an improved risk profile compared to opioids for pain management.
  • FDA’s device center will choose which applicants are accepted into the program in November. Those selected will have “enhanced interactions with FDA review divisions” during the development of their products, and FDA will grant the Breakthrough Device designation to products that meet the statutory criteria without requiring a separate application.

FDA expects that the products that go through the program will ultimately submit “one or more formal applications” for approval through its various device approval pathways.
“The FDA stands ready to provide significant assistance and expedite premarket review of applications to help bring innovative devices that, if properly instituted, could help those at risk for addiction or treat those who might develop opioid use disorder,” FDA device chief Jeff Shuren said in a statement.
The agency plugged the opportunity to work closely with the agency as an incentive for developers to create products that address the opioid crisis. Examples of desirable products include diagnostics that can identify those at high risk of addiction, treatments for pain that could replace opioids, treatments that could help alleviate opioid withdrawal symptoms and technologies that prevent illicit diversion of prescription opioids.
The innovation challenge builds upon HHS’ efforts to address the opioid crisis by encouraging the development of novel pain treatments, an element of its Five-point Strategy to Combat the Opioid Crisis.
The Centers for Disease Control and Prevention said in March that drug overdoses killed 63,632 Americans in 2016, with 66% of those deaths attributable to a prescription or illicit opioid. The surgeon general has said more Americans should carry around naloxone, which can reverse the effects of an opioid overdose.
As the opioid epidemic continues to take its devastating toll across the country, providers and payers have developed policies aimed at curbing misuse of the drugs. Prescribers are being asked to consider alternative pain management treatments and to check prescription drug monitoring programs. Some organizations are using data analyses to pinpoint patients who may be at high risk of opioid addiction in an attempt to stop a disorder before it starts.
“We’re hopeful that in collaborating with public health-minded innovators, we can identify and accelerate the development of new technologies, whether a device, diagnostic test, mobile medical app, or even new clinical decision support software, that can contribute in novel and effective ways to help reduce the scope of this crisis,” FDA Commissioner Scott Gottlieb said in a statement.
Also, both chambers of Congress are in the process of moving sizable packages of opioid bills aimed at further tackling the crisis. Cowen Washington Research Group predicts a package is likely to pass Congress before the August recess.

NYC Unveils Cocaine Safety Tips After Fentanyl Appears In Users Supply


New York City has a new method of warning people about the dangers of cocaine use: They’re telling them how to use it safely.
The move was prompted after the drug fentanyl was found to be laced in the cocaine supply.
View image on Twitter
nycHealthy
✔@nycHealthy
ICYMI: We’re warning patrons of bars/nightclubs on the Lower East Side about the dangers of cocaine laced with fentanyl: http://on.nyc.gov/2Lo0M6P 
Fentanyl is an opioid that’s 30-50 times more potent than heroin, according to the Health Department.

“People who may use cocaine occasionally may be at risk of an opioid overdose,” the Health Department said in a press release.
So Health Department officials have been visiting bars and clubs on the Lower East Side to spread the word. They’ve been passing out free coasters warning about fentanyl laced cocaine. The coasters include some safety tips: Those tips include using cocaine with others, so that in the event of an overdose there’s someone who could help. They also urge users to carry naloxone or narcan, which can reverse an overdose.
Users can call 311 to find out where to get naloxone. For treatment, users can call 888-NYC-WELL.
CBS2’s Andrea Grymes asked Mayor Bill de Blasio if he thought this would encourage cocaine use.
He said that people are using cocaine, so the city is doing whatever it can to get the message out.
“The city is not encouraging drug usage, we are encouraging safety,” officials said in a statement. ” We can’t connect New Yorkers to treatment if they are dead.”